论文部分内容阅读
目的探讨贝伐珠单抗联合双周方案一线治疗晚期大肠癌的临床疗效。方法 66例晚期大肠癌患者作为研究对象,随机分为对照组及研究组,各33例。研究组应用贝伐珠单抗联合双周方案一线治疗,对照组单纯应用双周方案化疗,比较两组患者的临床疗效。结果研究组患者治疗总有效率为78.8%,明显高于对照组的54.5%,差异具有统计学意义(P<0.05)。两组患者的化疗毒副反应主要表现为1~2级,其中肝功能受损发生率最高,研究组与对照组分别为27.3%与24.2%。两组化疗毒副反应发生情况对比差异无统计学意义(P>0.05)。结论晚期大肠癌患者应用贝伐珠单抗联合双周方案一线治疗能够获得良好的临床疗效,化疗毒副反应患者均能耐受,值得临床推广。
Objective To investigate the clinical efficacy of bevacizumab in combination with bifacial regimen in the treatment of advanced colorectal cancer. Methods Sixty-six patients with advanced colorectal cancer were randomly divided into control group and study group, with 33 cases in each group. The study group was treated with bevacizumab in combination with bifacial regimen and the control group with bifacial chemotherapy alone. The clinical efficacy of the two groups was compared. Results The total effective rate of treatment group was 78.8%, significantly higher than that of control group (54.5%), the difference was statistically significant (P <0.05). The two groups of patients with chemotherapy toxicity mainly in 1 to 2, of which the highest incidence of impaired liver function, the study group and the control group were 27.3% and 24.2%. There was no significant difference in the occurrence of chemotherapy side effects between the two groups (P> 0.05). Conclusions The first-line treatment of patients with advanced colorectal cancer combined with bevacizumab plus bifacial regimen can achieve good clinical efficacy. All patients with chemotherapy-induced toxicity are tolerant and worthy of clinical promotion.